No New Safety Concerns Have Been Identified After An J&J (JNJ) Booster Shot - Johnson & Johnson In FDA Presentation - Reuters
- Tech lifts S&P 500, Nasdaq amid inflation, China growth worries
- Zillow (ZG) Stock Falls on Report Company Paused Home Purchases due to High Demand, a Temporary Halt Yields a Chance for Competitors Says Analyst
- Oil prices ease off highs as U.S. factory data weighs on market
- Chip Shortages are Increasingly Becoming a New Bearish Risk, Inflation Bearish for Consumer Electronics - TFI's Kuo
- Walt Disney (DIS) Stock Slips as Barclays Downgrades Amid Disney+ Growth Slowdown
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
No New Safety Concerns Have Been Identified After An Johnson & Johnson (NYSE: JNJ) Booster Shot - Johnson & Johnson In FDA Presentation - Reuters
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CRL is a Negative, but Omeros (OMER) Stock is Trading Far Below Fundamental Value - Analyst
- Johnson & Johnson (JNJ) IV into FDA decision on cilta-cel
- FDA backs Johnson & Johnson (JNJ) booster shot for people 18 and older at least 2 months after first dose
Create E-mail Alert Related CategoriesCorporate News, FDA, Rumors, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!